We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Honeybee Propolis Extract Impedes Prostate Cancer Cell Growth

By LabMedica International staff writers
Posted on 14 May 2012
Cancer researchers have discovered the molecular mechanism that utilizes the honeybee propolis component caffeic acid phenethyl ester (CAPE) to arrest the growth of prostate cancer cells in culture and in mouse xenografts.

CAPE is a bioactive component derived from honeybee hive propolis. More...
It has been shown to have antimitogenic, anticarcinogenic, and other beneficial medicinal properties. Many of its effects have been shown to be mediated through its inhibition of NF-kappaB signaling pathways. Notably, CAPE down-regulates the mdr-1 gene, considered responsible for the resistance of cancer cells to chemotherapeutic agents.

In the current study investigator at the University of Chicago (IL, USA) employed a systematic approach to uncover the long- and short- term effects of CAPE on the signaling networks in human prostate cancer cells.

They reported in the May 1, 2012, issue of the journal Cancer Prevention Research that dosages of CAPE dependently suppressed the proliferation in culture of the LNCaP, DU-145, and PC-3 lines of human prostate cancer cells. Furthermore, administration of CAPE significantly inhibited growth of LNCaP tumor xenografts in nude mice.

Working with LNCaP cells as a model system, the investigators examined the effect of CAPE on gene expression, protein signaling, and transcriptional regulatory networks using a novel series of micro-Western and PCR arrays. They found that CAPE acted through inhibition of Akt-related protein signaling networks. Akt, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. Overexpression of Akt-1 or c-Myc (v-myc myelocytomatosis viral oncogene homolog), a downstream target of Akt signaling, significantly blocked the antiproliferative effects of CAPE.

“If you feed CAPE to mice daily, their tumors will stop growing. After several weeks, if you stop the treatment, the tumors will begin to grow again at their original pace,” said senior author Dr. Richard B. Jones, assistant professor of genomics and systems biology at the University of Chicago. “So it does not kill the cancer, but it basically will indefinitely stop prostate cancer proliferation.”

“It appears that CAPE basically stops the ability of prostate cancer cells to sense that there is nutrition available. They stop all of the molecular signatures that would suggest that nutrition exists, and the cells no longer have that proliferative response to nutrition,” said Dr. Jones. “A typical problem in bringing some of these herbal remedies into the clinic is that nobody knows how they act, nobody knows the mechanism, and therefore researchers are typically very hesitant to add them to any pharmaceutical treatment strategy. Now we will actually be able to systematically demonstrate the parts of cell physiology that are affected by these compounds.”

Related Links:

University of Chicago



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.